NCT02636933

Brief Summary

The PRE-AR project is a longitudinal observational study. The primary objective is the assessment of lung function parameters in late preterm preschool children.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
152

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2015

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2015

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 2, 2015

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 22, 2015

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

April 14, 2026

Status Verified

April 1, 2026

Enrollment Period

4.9 years

First QC Date

October 2, 2015

Last Update Submit

April 9, 2026

Conditions

Keywords

AsthmaAllergic RhinitisChildrenAtopy

Outcome Measures

Primary Outcomes (3)

  • Forced oscillation technique

    Longitudinal assessment of forced oscillation technique (FOT)

    Baseline, 24 months, and 48 months

  • Spirometry

    Longitudinal assessment of spirometry

    Baseline, 24 months, and 48 months

  • Interrupter resistance

    Longitudinal assessment of interrupter resistance (RINT)

    Baseline, 24 months, and 48 months

Secondary Outcomes (5)

  • Nasal nitric oxide

    Baseline, 24 months, and 48 months

  • Atopy

    Baseline

  • Nasal brushing

    Baseline

  • Saliva sample

    24 months, and 48 months

  • Urine analysis

    Baseline, 24 months, and 48 months

Study Arms (2)

59 prematurely born children

Lung function assessment of 59 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology \& Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR)

Other: Lung Function Assessment

93 full-term born children

Lung function assessment of a Control group of full-term born children (N=93), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.

Other: Lung Function Assessment

Interventions

Lung Function Assessment

59 prematurely born children93 full-term born children

Eligibility Criteria

Age3 Years - 5 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

A study population of 59 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology \& Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR). A Control group of full-term born children (N=93), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy. The subjects will be paired up according to the sex and to the age, with a ratio 1:1.

You may qualify if:

  • Premature birth \< 37 weeks
  • years old ≤ Age ≥ 3 years old
  • Control group
  • Full-term birth
  • years old ≤ Age ≥ 3 years old

You may not qualify if:

  • Pulmonary bronchodysplasia (BDP)
  • Acute respiratory infection
  • Immunological and metabolic system disease
  • Malformation of upper respiratory tract
  • Topical or systemic therapies, with antibiotics, antihistaminics and corticosteroids, in the previous 30 days
  • Patients with neurological pathologies
  • Patients that are not able to perform the lung function tests

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Biomedicine and Molecular Immunology, IBIM

Palermo, Palermo, 90146, Italy

Location

MeSH Terms

Conditions

AsthmaRhinitis, Allergic

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesRhinitisNose DiseasesOtorhinolaryngologic Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Stefania La Grutta, MD. Senior Researcher. Coordinator of Pediatric Allergy and Asthma Research Group. Institute of Biomedicine and Molecular Immunology, IBIM, National Research Council of Palermo, Italy.

Study Record Dates

First Submitted

October 2, 2015

First Posted

December 22, 2015

Study Start

March 1, 2015

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

April 14, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

The IPD collected will be available on december 2023. The following participant data will be shared: * Pulmonary function tests * Demographic characteristics All IPD will be obtained from statistical analysis on the dedicated database in which all data are stored.

Locations